{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transfusion-dependent+Alpha-Thalassemia",
    "query": {
      "condition": "Transfusion-dependent Alpha-Thalassemia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:46:59.038Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00873041",
      "title": "Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-transfusion Dependent Thalassemia"
      ],
      "interventions": [
        {
          "name": "deferasirox",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2008-11",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-07-09",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00873041"
    },
    {
      "nct_id": "NCT01419704",
      "title": "Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia, Sickle Cell",
        "Complex and Transfusion-dependent Hemoglobinopathies",
        "Thalassemia",
        "Diamond-Blackfan Anemia",
        "Bone Marrow Failure Syndromes",
        "Alpha-Thalassemia",
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Enriched Hematopoetic Stem Cell Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Talaris Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-05",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01419704"
    },
    {
      "nct_id": "NCT04987489",
      "title": "A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Etavopivat tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forma Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 53,
      "start_date": "2022-03-28",
      "completion_date": "2025-09-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 14,
      "location_summary": "Cerritos, California • Los Angeles, California • Oakland, California + 9 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987489"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT04770753",
      "title": "A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Transfusion-dependent Alpha-Thalassemia",
        "Non-Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Placebo Matching Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2021-12-20",
      "completion_date": "2028-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Palo Alto, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770753"
    },
    {
      "nct_id": "NCT04770779",
      "title": "A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transfusion-dependent Alpha-Thalassemia",
        "Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Placebo Matching Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-11-30",
      "completion_date": "2029-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Oakland, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770779"
    },
    {
      "nct_id": "NCT02179359",
      "title": "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Transfusion Dependent Alpha- or Beta- Thalassemia",
        "Diamond Blackfan Anemia",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Glanzmann Thrombasthenia",
        "Severe Congenital Neutropenia",
        "Shwachman-Diamond Syndrome",
        "Non-Malignant Hematologic Disorders"
      ],
      "interventions": [
        {
          "name": "Reduced Toxicity Ablative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity Preparative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Preparative Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2014-09-02",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-05-22T09:46:59.038Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02179359"
    }
  ]
}